Viruses, Volume 17, Issue 1
2025 January - 135 articles
Cover Story: The recent monkeypox (mpox) outbreak in Central Africa and its worldwide spread led the WHO to declare a public health emergency of international concern. The limited efficacy of tecovirimat (TPOXX), an FDA-approved small-molecule antiviral recommended to treat mpox cases with severe symptoms, and the emergence of TPOXX-resistant MPXV have highlighted the urgent need for alternative therapeutic strategies. In this study, we provide evidence that the combination therapy of TPOXX together with mycophenolate mofetil (MMF), or the N-myristoyltransferase (NMT) inhibitor IMP-1088, as well as the combination of MMF and IMP-1088, exhibit strong dose-dependent synergistic antiviral activity against MPXV. Our findings support the combination therapy of direct-acting (TPOXX) and host-targeted (MMF and IMP-1088) antivirals as a promising approach to treating mpox. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.